Prevduo Injection
NDC Package 42023-269-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Prevduo (neostigmine methylsulfate and glycopyrrolate) injection is pREVDUOTM, a fixed dose combination of cholinesterase inhibitor and antimuscarinic agent, is indicated in patients age two years and above for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration. This formulation utilizes a injection delivery system. Marketed by Endo Usa, this product is identified by NDC 42023-269 and is authorized under FDA application NDA216903.

Identification & Billing

NDC Package Code
42023-269-05
Package Description
5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC (42023-269-01)
Product Code
42023-269
11-Digit Billing Format
42023026905
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2637041 - neostigmine methylsulfate 3 MG / glycopyrrolate 0.6 MG in 3 ML Prefilled Syringe
  • RxCUI: 2637041 - 3 ML glycopyrrolate 0.2 MG/ML / neostigmine methylsulfate 1 MG/ML Prefilled Syringe
  • RxCUI: 2637041 - neostigmine methylsulfate 3 MG / glycopyrrolate 0.6 MG per 3 ML Prefilled Syringe
  • RxCUI: 2637047 - PREVDUO 3 MG / 0.6 MG in 3 ML Prefilled Syringe
  • RxCUI: 2637047 - 3 ML glycopyrrolate 0.2 MG/ML / neostigmine methylsulfate 1 MG/ML Prefilled Syringe [Prevduo]

Clinical Specifications

Proprietary Name
Prevduo
Non-Proprietary Name
Neostigmine Methylsulfate And Glycopyrrolate
Substance Name
Glycopyrrolate; Neostigmine Methylsulfate
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
PREVDUOTM, a fixed dose combination of cholinesterase inhibitor and antimuscarinic agent, is indicated in patients age two years and above for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration.

Regulatory & Marketing

Labeler Name
Endo Usa
Product Type
Human Prescription Drug
FDA Application #
NDA216903
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-15-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42023-269-05 identifies a specific commercial package of 5 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic (42023-269-01) of Prevduo, a human prescription drug labeled by Endo Usa. This injection is formulated for intravenous use and contains glycopyrrolate; neostigmine methylsulfate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Endo Usa on May 15, 2023. The current certification is valid through December 31, 2026.

How is this Endo Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42023026905. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42023-269-05
11-Digit CMS (5-4-2)
42023-0269-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.